Ketamine for Pain: A New Way to Manage Acute Pain (Shi et al., 2024)
Introduction: In January 2024, Shi and colleagues published a study in the Journal of the College of Physicians and Surgeons […]
Condition
Mechanisms and Clinical Applications of Ketamine Variants in Depression (Kawczak et al., 2024)
Introduction: Kawczak et al.’s 2024 review in Biomedicines explores ketamine, esketamine, and arketamine’s mechanisms of action and their applications in
Ketamine and Its Variants: Unlocking New Hope for Depression (Kawczak et al., 2024)
Introduction: In October 2024, Kawczak and colleagues published an in-depth review in Biomedicines discussing ketamine and its variants (esketamine and
Clinical Trial Insights: Ketamine’s Expanding Role in Psychiatry (Peyrovian et al., 2020)
Introduction: Peyrovian et al.’s 2020 review in the Journal of Psychiatric Research summarizes registered clinical trials evaluating ketamine for psychiatric
Ketamine’s Role in Mental Health Treatment: New Hope from Clinical Trials (Peyrovian et al., 2020)
Introduction: In 2020, Peyrovian and colleagues published an analysis of registered clinical trials investigating ketamine as a treatment for psychiatric
Ketamine Pilot Study for Late-Life Depression: Early Insights (Lenze, ClinicalTrials.gov, 2020)
Introduction: Dr. Eric Lenze’s 2020 pilot study investigates ketamine’s safety and efficacy in older adults with treatment-resistant depression (TRD). This
Exploring Ketamine for Older Adults: A Groundbreaking Pilot Study (Lenze, ClinicalTrials.gov, 2020)
Introduction: In 2020, Dr. Eric Lenze and his team launched a pilot study to explore how ketamine might help older
Esketamine: A Paradigm Shift in TRD Treatment (Kim et al., NEJM, 2019)
Introduction: Kim and colleagues’ 2019 article in The New England Journal of Medicine reviews the groundbreaking approval of esketamine as
Esketamine: A Groundbreaking Antidepressant Explained (Kim et al., NEJM, 2019)
Introduction: In 2019, a team of experts published an article in The New England Journal of Medicine highlighting the significance
Esketamine: A Fast-Acting Treatment for Depression, Explained (Hough, FDA, 2019)
Introduction: In 2019, the FDA approved esketamine, a nasal spray developed for people with treatment-resistant depression (TRD). This report by